Format

Send to

Choose Destination
Expert Rev Gastroenterol Hepatol. 2016;10(2):165-75. doi: 10.1586/17474124.2016.1123618. Epub 2015 Dec 15.

Vedolizumab for the treatment of ulcerative colitis.

Author information

1
a Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases) , University Hospital Jena , Jena , Germany.
2
b Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten , Leipzig , Germany.

Abstract

A substantial proportion of patients with ulcerative colitis (UC) have failed conventional therapies such as steroids, immunosuppressants or TNF-antibodies, or have experienced side effects. This article reviews the pharmacological properties of vedolizumab (VDZ), its efficacy and side effects in UC. By its relatively specific gut-selective mode of action, VDZ's safety profile appears more favorable than that of anti-TNF therapies. VDZ is more effective than placebo for the induction and maintenance of remission in moderate-to-severe UC in both naïve patients and patients who have failed anti-TNF treatment. However, in some patients, VDZ has a slower onset of action. But, to place VDZ as a first-line therapy, it must go head-to-head with azathioprine and anti-TNF antibodies in future studies.

KEYWORDS:

Vedolizumab; efficacy; pharmacokinetics; side effects; ulcerative colitis

PMID:
26588993
DOI:
10.1586/17474124.2016.1123618
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center